View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 13, 2019updated 16 May 2019 3:01pm

Oncimmune to trial EarlyCDT-Lung test in China

UK-based immunodiagnostics developer Oncimmune, in alliance with Genostics, has initiated a multi-centre clinical trial of its EarlyCDT-Lung test in the People’s Republic of China.

UK-based immunodiagnostics developer Oncimmune, in alliance with Genostics, has initiated a multi-centre clinical trial of its EarlyCDT-Lung test in the People’s Republic of China.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

Designed to enable early detection of lung cancer, EarlyCDT-Lung is a blood test that measures the levels of seven autoantibodies to tumour-associated antigens associated with lung cancer.

As these seven autoantibodies are known to be elevated in all types of lung cancer and from the earliest stage, the test is expected to be able to identify all types of the cancer at all stages (I-IV).

The test runs on a simple enzyme-linked immunosorbent assay (ELISA) platform. Oncimmune noted that EarlyCDT-Lung could detect the cancer nearly four years or more before clinical diagnosis using standard care pathways.

Oncimmune CEO Adam Hill said: “This study is part of our ongoing programme to support the introduction of EarlyCDT-Lung in China, which is progressing to schedule.

“We welcome this initiative and the commitment of our partner Genostics in supporting the introduction of EarlyCDT-Lung into what is one of the world’s largest markets.”

The multi-centre, case-control trial will involve an extended panel of autoantibodies in order to include variations in the biomarkers expressed on cancer cells in Asian populations.

“We welcome this initiative and the commitment of our partner Genostics.”

It will be conducted for around 1,000 early lung cancers at five academic health centres in China. Professor Bai from the Pulmonary Medicine department at Zhongshan Hospital, Fudan University, will lead the study.

Results from the study are expected to be available in the fourth quarter of this year. The company anticipates that the study data will support its application for EarlyCDT-Lung approval in China.

EarlyCDT-Lung is also being studied by the National Health Service (NHS) in a randomised trial for the early detection of lung cancer using biomarkers.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network